Iomai — Merger or Acquisition (May 2008)
36 slides from Iomai's merger presentation, May 13, 2008
Slide 1: Driving Vaccine Innovation – Roadshow Presentation
Driving Vaccine Innovation ROADSHOW PRESENTATION Intercell develops vaccines for the prevention and treatment of infectious diseases For more information be invited to: www.intercell.com
Slide 2: Safe Harbour Statement
Safe Harbour Statement These materials do not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities. During the course of this presentation, Intercell AG (the “Company”) may make projections or other forward-looking statements regar
Slide 3: Delivering on promises — dedication to innovation
Delivering on promises — dedication to innovation KEY MANAGEMENT Gerd Zettlmeissl, CEO Former CEO of Chiron Behring, co-inventor of Enbrel Werner Lanthaler, CFO Former Senior Consultant with McKinsey & Company, former Executive Director with the Federation of Austrian Industry Alexander von Gabain,
Slide 4: Agenda Overview
Agenda Overview Introduction to Iomai — The Target Company Deal Rationale & Product Development Update Q1 2008: Results & Strategic Implications Intercell Going Forward PAGE 3 ROADSHOW PRESENTATION MAY 2008
Slide 5: A combination of cash and share consideration secures competitive deal
A combination of cash and share consideration secures competitive deal IOMAI TRANSACTION OVERVIEW Acquirer Intercell (VSE:ICLL) Target Iomai (NASDAQ: IOMI) $6.60 per share Total consideration of $189m* ( € 122m) Offer Value ??$70m ( € 45m) in new shares** ??$119m ( € 77m) in cash Share Exchange: bet
Slide 6: Acquisition of Iomai — adding late stage products and vaccine patch
Acquisition of Iomai — adding late stage products and vaccine patch IOMAI ACQUISITION STRATEGIC RATIONALE Even stronger, more diversified late stage vaccine portfolio Leading travelers’ vaccine franchise targeting > € 750m combined market (JEV, Travelers’ Diarrhea) Promising Flu vaccine patch franch
Slide 7: Focus of R&D Day: our value proposition
Focus of R&D Day: hospital acquired infections, travelers’ franchise and innovative vaccine patch technology OUR VALUE PROPOSITION Technologies Products AIP ® New global travelers’ vaccines Leading technology Japanese Encephalitis vaccine — expected market generating novel approval US/EU/AUS 2008, I
Slide 8: Agenda Overview
Agenda Overview Introduction to Iomai — The Target Company Deal Rationale & Product Development Update Q1 2008: Results & Strategic Implications Intercell Going Forward PAGE 7 ROADSHOW PRESENTATION MAY 2008
Slide 9: Perfect match for our growth — advanced products and new delivery technology
Perfect match for our growth — advanced products and new delivery technology COMPANY SNAPSHOT Late stage products targeting significant infectious disease opportunities Travelers’ Diarrhea vaccine patch (> € 0.5bn market opportunity) Vaccine enhancement patch for Pandemic Flu ( € 0.5-1.0bn market op
Slide 10: Travelers' Diarrhea: substantial unmet medical need
Travelers’ Diarrhea: substantial unmet medical need RISK AREAS FOR TRAVELERS — OVERVIEW Significant risk for travelers to the developing world Increasing number of business travelers to “at risk” regions 55 m travelers from developed countries to endemic areas People at risk for TD growing at 3.6% C
Slide 11: Travelers' Diarrhea — incidence and etiology
Low Risk Intermediate Risk High Risk 19 m travelers each year to contract Travelers’ Diarrhea — ETEC as the main cause TRAVELERS’ DIARRHEA — INCIDENCE AND ETIOLOGY (2007) Population 425m 54.7m 19.2m 100% 100% Unknown 90% Protozoa Viruses 80% Other Bacteria 70% Shigella No TD Salmonella 60% To non- e
Slide 12: Immunogenicity and efficacy proof for Travelers' Diarrhea vaccine patch
Immunogenicity and efficacy proof for Travelers’ Diarrhea vaccine patch OVERVIEW OF PHASE II RESULTS* Vaccinees (n=59) Placebo (n=111) Excellent immunogenicity** LT IgG GMT LT IgA GMT 12,000 500 450 10,000 400 350 8,000 300 6,000 250 200 4,000 150 100 2,000 50 0 0 Baseline Arrival in Exit Baseline A
Slide 13: Travelers' diarrhea vaccine patch shows excellent efficacy and safety profile in Phase II
Travelers’ diarrhea vaccine patch shows excellent efficacy and safety profile in Phase II EFFICACY AND SAFETY — CONCLUSIONS* The Travelers’ Diarrhea vaccine patch Prevents Diarrhea and ETEC infections 75% reduction of moderate and severe Travelers’ Diarrhea 84% reduction of severe Travelers’ Diarrhe
Slide 14: High likelihood of bringing Travelers' Diarrhea vaccine patch to market
High likelihood of bringing Travelers’ Diarrhea vaccine patch to market DEVELOPMENT AND REGULATORY PATHWAY 2006/2007 2008/2009 2010/2011 Phase II efficacy data Preparation and start of global pivotal Phase III Pivotal Phase III efficacy data Production of patches at commercial scale efficacy studies
Slide 15: A "one dose" Pandemic Flu vaccine patch is urgently needed
A “one dose” Pandemic Flu vaccine patch is urgently needed PROBLEM AND CURRENT STATUS Permanent threat of a global pandemic outbreak Need to vaccinate total population with fast protection ?Lower antigen doses ?Protection with one dose vaccine Currently only US approved pandemic vaccine with subopti
Slide 16: Vaccine enhancement patch strongly increases Pandemic Flu immune response after one dose
Vaccine enhancement patch strongly increases Pandemic Flu immune response after one dose* PHASE I/II DATA Study design Study vaccine ?Injectable derived H5N1 Flu** ?With/without patch on injection site 10 study groups (~ 500 subjects total) Endpoints ?Protective immune responses*** ?Systemic and loc
Slide 17: Agenda Overview
Agenda Overview Introduction to Iomai — The Target Company Deal Rationale & Product Development Update Q1 2008: Results & Strategic Implications Intercell Going Forward PAGE 16 ROADSHOW PRESENTATION MAY 2008
Slide 18: Strong late stage portfolio addressing high unmet medical need
Strong late stage portfolio addressing high unmet medical need COMBINED INTERCELL PORTFOLIO — SNAPSHOT Market size > € 1.5bn Market size € 500m — 1.5bn Market size < € 500m Iomai Market opportunity Pneumo HCV S. aureus High Flu (IC31 ® )Pseudo- Travelers’ monas Diarrhea Moderate Japanese Encephaliti
Slide 19: Even stronger pipeline and definitive leadership in vaccines innovation
Even stronger pipeline and definitive leadership in vaccines innovation PRODUCT DEVELOPMENT Clinical vaccines Status Expected milestones Partner 1. Japanese Encephalitis Prophylactic Filed US/EU/AUS/India market Novartis (M&D) / Virus vaccine approvals in 2008/09 CSL / Bio. E 2. Travelers’ Diarrhea
Slide 20: Leading patch technology for vaccine delivery
Leading patch technology for vaccine delivery OVERVIEW TRANSCUTANEOUS IMMUNIZATION (TCI) Vaccine Delivery via a patch Vaccine patch APCs* Epidermis Vaccine +/-Adjuvant Migration Dermis Activated APCs Draining Lymph Node Ease of use and needle-free administration (self applied) Direct antigen and adj
Slide 21: Numerous applications for vaccine patch (TCI)
Numerous applications for vaccine patch (TCI) POTENTIAL STRATEGIC APPLICATIONS Direct antigen/adjuvant delivery, e.g. TD vaccine patch (Phase II) Pneumococcus vaccine patch Many others Vaccine enhancement patch*, e.g. Pandemic Flu (Phase I/II) 2nd generation JEV (one dose) Reduction of injections fo
Slide 22: A leading travelers' vaccine franchise
A leading travelers’ vaccine franchise SYNERGY 1/3 JAPANESE ENCEPHALITIS 30,000-50,000 cases p.a. 25% fatality rate ~28m travelers to endemic areas p.a. Market Opportunity ~ € 250—350m Leading global JEV franchise Filed — expected market approval in US/EU/AUS in 2008 and India in 2009 No competing p
Slide 23: A promising Flu vaccine technology franchise
A promising Flu vaccine technology franchise SYNERGY 2/3 IC31 ® + FLU 100,000 ~ 200,000 deaths per year in US/EU Leading global franchise for Insufficient protection of better Flu vaccine for elderly elderly/risk populations Phase II data expected 2009 Limited competition Market Opportunity ~ € 2bn
Slide 24: Combination of complementary and industry leading technology platforms
Combination of complementary and industry leading technology platforms SYNERGY 3/3 ANTIGEN ADJUVANTS Antigen Identification Vaccine Improvement Program (AIP ® ) Program (VIP ® ) Antigens for new Leading B-cell and vaccine candidates T-cell adjuvants ?S. aureus ?IC30 ?Pneumococcus ?IC31 ® ?Borrelia ?
Slide 25: Strongest antigen delivery franchise in industry
Strongest antigen delivery franchise in industry VACCINE INNOVATION TECHNOLOGY: AIP ® Antigen Identification Program (AIP ® ) Partner Pathogen Total repertoire of Identified potential antigens Antigens Bacterial genome Antibodies Antibodies of humans exposed to the disease select protective antigens
Slide 26: Execution on "JEV to All Markets"
Execution on “JEV to All Markets” DEVELOPMENT AND REGULATORY PATHWAY 2005 2006 2008/2009 Production of Interim safety data ? Build up commercial Phase III material ? Decision on orphan drug manufacturing and supply Pivotal Phase III clinical status in EU ? chain ? trials started in September Complet
Slide 27: A highest priority program with Merck
A highest priority program with Merck S. AUREUS DEVELOPMENT AND REGULATORY PATHWAY Until 2007 2008/20092010/2011 Extensive pre-clinicalPotential expansion of» Pivotal Phase III data program/animal indication areas (e.g.,» Phase III safety and studies dialysis) consistency data Broad Phase I study Ph
Slide 28: A straight forward development in hospital acquired infections
A straight forward development in hospital acquired infections PSEUDOMONAS DEVELOPMENT AND REGULATORY PATHWAY Until 2007 2008/20092010/2011/2012 Extensive pre-clinical »Production of clinical » Start of pivotal Phase III evaluation/animal Phase II/III materials» Pivotal Phase III data models ?» Star
Slide 29: Agenda Overview
Agenda Overview Introduction to Iomai — The Target Company Deal Rationale & Product Development Update Q1 2008: Results & Strategic Implications Intercell Going Forward PAGE 29 ROADSHOW PRESENTATION MAY 2008
Slide 30: Strong financial and strategic position — Excellent fundamentals for further growth
Strong financial and strategic position — Excellent fundamentals for further growth KEY FIGURES* — OVERVIEW “e” = expected Net loss / profit, in EUR m 2005 2006 2007 Q1 08 2008e 5.0 -4.6 -16.1 -25.0 Profitability expected despite Iomai acquisition Cash, in EUR m 287.6 272.2** 94.4 50.2 2005 2006 200
Slide 31: Agenda Overview
Agenda Overview Introduction to Iomai — The Target Company Deal Rationale & Product Development Update Q1 2008: Results & Strategic Implications Intercell Going Forward PAGE 31 ROADSHOW PRESENTATION MAY 2008
Slide 32: Highly efficient integration process in place from day one
Highly efficient integration process in place from day 1 ROADMAP FOR IOMAI INTEGRATION Signing to closingChange of controlShort term integration Full operational integration Mid May -Day 1Day 100 Day 365 Timing Q3 2008 Joint Steering» Interim ICLL» Interim ICLL » Full matrix Gover- CommitteeMgmt Tea
Slide 33: Acceleration of growth strategy on strong fundamentals
Acceleration of growth strategy on strong fundamentals INTERCELL STRATEGY Value Today Acceleration of product development (e.g., Pneumo, Travelers’ Diarrhea, antibodies, ...) World-class strategic alliances to leverage technologies, diversify risk, and to get access to key markets e.g.: Product sale
Slide 34: Strong people and solid shareholders
Strong people and solid shareholders SHAREHOLDER STRUCTURE* Management Treasury shares Kapital & Wert 2.0% 0.8% Temasek 4.3% Holdings 8.7% Novartis 15.9% 68.3% Free float Management Team Locations G. Zettlmeissl (CEO) Vienna (Austria) A. von Gabain (CSO) Livingston (Scotland) W. Lanthaler (CFO) Moor
Slide 35: Next steps... selected next milestones
Next steps... SELECTED NEXT MILESTONES MHRA commercial license ? Filing in Australia ? Results of Phase II clinical trials in children in endemic countries ? JEV vaccine Agreement with US Army Marketing agreement for Japanese market Market approvals in US, EU, Australia and India Hospital Phase II r
Slide 36: Questions & Answers
QUESTIONS & ANSWERS SMART VACCINES For more information be invited to: www.intercell.com